

TAKE Solutions Ltd. Announces Results for the Quarter ended September 30, 2011

Chennai, India – October 28, 2011

Highlights:

- **Consolidated second quarter revenue grew to INR 1,709 million up 44.0% y-o-y**
- **Net profit up 24.0% y-o-y to INR 202 million**
- **EBITDA margin at 22.5%**
- **Diluted Earnings per share (EPS): INR 1.68**
- **Order book at USD 72.1 million**
- **Recognized as the leader in the Life Sciences R&D IT segment**

QUARTER ENDED SEPTEMBER 30, 2011

TAKE Solutions' consolidated revenue was INR 1,709 million for the quarter ended September 30, 2011. It represents 44.0% increase over the same period last year and 6.2% rise over first quarter of FY12 ended June 30, 2011.

Earnings Before Interest, Tax, Depreciation and Amortization (EBITDA) for the quarter was INR 385 million up 47.2% y-o-y and 6.6% q-o-q. The EBITDA margin for the quarter was 22.5% compared to 22.4% in Q1 FY12.

Net Profit for the quarter ended September 30, 2011 was INR 202 million. This represents an increase of 24.0% over the same period last year and decline of 6.5% over the June, 2011 quarter. The strong growth in operating profit was offset by higher tax rates. The effective tax rate for the quarter was 22.2% compared to 18.9% in Q1 FY12. The EPS for the period was INR 1.68.

	Q2 FY12 (INR mn)	Y-o-Y change (%)	H1 FY12 (INR mn)	Y-o-Y change (%)
Total Revenue	1,709	44.0%	3,318	45.3%
EBITDA	385	47.2%	746	47.5%
Net Profit	202	24.0%	418	36.5%
Diluted Earnings Per Share (INR)	1.68	23.9%	3.48	36.7%

SIX MONTHS ENDED SEPTEMBER 30, 2011


For the six months ended September 30, 2011, consolidated revenue was INR 3,318 million, a growth of 45.3% increase over the same period last year. EBITDA was INR 746 million up 47.5% y-o-y. The EBITDA

margin for the period was 22.5% compared to 22.1% for the six months ended September 30, 2010. Net Profit for the year till date was INR 418 million, a 36.5% increase over the corresponding period of FY 2011. The EPS for the period was INR 3.48.

INDUSTRY RECOGNITION

TAKE received a “*Leader*” rating in IDC Health Insights’ MarketScope: Worldwide Life Sciences R&D IT Outsourcing Report 2011 Vendor Assessment. The “leader” category is the report’s highest ranking.

The IDC Health Insights study assesses industry-specific offerings and experience, deployment flexibility, strength and responsiveness to project challenges, and long-term vendor growth strategies. Evaluation is based on a comprehensive framework and set of parameters expected to be conducive to a success in life sciences R&D IT outsourcing services and emerging growth in both the short-term and long-term.



Source: IDC MarketScope: Worldwide Life Science R&D IT Outsourcing 2011 Vendor Assessment, August 2011

According to IDC:

- “TAKE has built a strong list of clients, based on its deep domain knowledge, willingness to engage customers as partners, IP-based solutions, and thought leadership in clinical, regulatory, drug safety, and other life science areas”
- “TAKE's diverse customer base, broad services portfolio, strong commitment to life science industry-specific growth, domain-centric expertise, and strong customer relationships make TAKE a fierce competitor in winning projects that the company competes for”

In 2010, TAKE was also recognized for its highest scores for customer service, and tied for first place in both life science industry expertise and overall customer satisfaction in IDC's Vendor Assessment: Life Science Buyer's Guide to Sales and Marketing IT Outsourcing.

NEW OFFERINGS

- **Launched Gemini R12.0c**, an upgrade for process and discrete manufacturers to automatically collect data using radio-frequency (RF) devices to increase the availability of information on receiving, shipping, manufacturing and inventory activity as it happens. In the new release, transactions to automate batch manufacturing, quality sampling and lot traceability have been specifically developed to meet the needs of process manufacturers, ensuring speed and accuracy on the shop floor.
- **Launched the extension of our SCM data collection services** with the launch of a dedicated Enterprise Mobility practice for Oracle E-Business Suite customers. The practice delivers Supply Chain mobility expertise coupled with the ability to accelerate business processes to help speed implementations of Oracle Warehouse Management and Oracle Mobile Supply Chain Applications without expensive customizations.
- **Enhanced our LS Safety and Pharmacovigilance services** with the launch of SafetyReady for Oracle customers. The solution helps accelerate implementation for life sciences organizations looking to jumpstart Safety & Pharmacovigilance adoption efforts and operations planning in as little as five weeks. For small to medium-sized businesses with limited resources and staff constraints, TAKE offers SafetyReady Cloud, an on-demand option that provides easy deployment and maintenance of critical applications. TAKE's SafetyReady suite also includes SafetyReady Upgrade and SafetyReady Migrate, modules to ease upgrades and migration to Oracle Argus Safety Suite. TAKE has leveraged the Safety & Pharmacovigilance functional expertise acquired through its subsidiary WCI Consulting, and has also developed tools and accelerators that will speed up the implementation process, reducing the cost while delivering quality.

BUSINESS OVERVIEW

- TAKE witnessed stable growth in the US whereas the Middle East Asia region performed better than expected. In Europe, the macroeconomic headwind continued to impact our business and we expect that the business environment will continue to be challenging for the next two quarters.
- During the quarter, we extended our relationship with one of our major SCM clients on the SaaS platform, OneSCM. Furthermore we are seeing the order pipeline for our SaaS offering growing.
- We won a project from a high-end supermarket chain in the Middle East for its UAE and Oman operations.
- All of our SCM clients, which upgraded to the new version of Oracle ERP retained our collaboration offering, Gemini, which is highly satisfying as this will lead to further long term relationship with the existing clients.

- In Life Sciences, we continued our focus on consolidating our position with the large pharmaceutical companies. In line with this, we are expanding the capacity in anticipation of large orders from big Life Sciences clients.
- We bagged a number of new opportunities particularly in the Clinical Supplies and Compliance programme implementation.
- During the quarter, we also saw increase in the deals in the Business Intelligence space from the existing and new clients.
- We also won new SCM order for a US based LS customer in the area of serialization and track & trace.

SALES TEAM STRENGTHENED

TAKE appointed Mr. John Levey as Vice President of Sales for its Supply Chain business. With more than 20 years of sales leadership experience in the software industry, John will oversee the growth of TAKE's sales team and the acceleration of global expansion efforts across the Company's supply chain division, including vertical markets: food/beverage, high-tech manufacturing, oil/gas, pharmaceuticals, and automotive.

John has held sales management positions at a number of high profile Companies including Oracle Corporation and SAP America, Inc. Most recently, he served as Sales Vice President for SAP America, where he managed a team responsible for Enterprise Accounts across the Southwest USA. Prior to SAP, he was employed with Oracle Corporation as an Area Sales Vice President responsible for Oracle's technology business across the Central USA and Canada.

PARTNERSHIP

TAKE extended its partnership with QlikTech (Nasdaq: QLIK) a leader in Business Discovery — user-driven Business Intelligence, to India. Both TAKE and QlikTech have been working towards identifying opportunities to drive efficiencies for its clients' businesses. Now this alliance, which began in 2009 in the USA, is expected to expand to other countries where TAKE Solutions have their operations. TAKE's QlikView Center of Excellence has certified QlikView specialists creating solutions like Drug Safety Analytics, Pharma Sales Force Analytics, Customer Intelligence, Supply Chain Collaboration Analytics and Spend Analytics.

ORDER BOOK

Due to prevailing macroeconomic uncertainty, the order book at the end of Q2 FY12 was flat compared to Q1 FY12. We ended Q2 FY12 with a total order book of USD 72.1 million. Life Sciences order book stood at USD 38.4 million while the Supply Chain Management business closed the quarter with USD 33.7 million.

OUTLOOK

We are cautiously optimistic for the rest of the year as we are closely monitoring the budget allocation, which will get finalized by our clients by this calendar year end as in the current uncertain macroeconomic environment there might be a shortfall compared to our expectation.

We will continue our focus on enhancing our existing offerings and also launch new offerings primarily on the SaaS platform to provide more value to our clients and not only cost advantage.

KEY BALANCE SHEET FIGURES




Particulars as on September 30, 2011	
Book Value Per Share (INR)	28
Net Worth (INR million)	3,404
Debtors Days	82
Debt (INR million)	1,866
Cash & Cash Equivalents (INR million)	1,056

CONSOLIDATED PROFIT AND LOSS ACCOUNT FOR THE QUARTER ENDED **SEPTEMBER 30, 2011**




All figures are in INR million, except per share data

	Quarter Ended		Half Year Ended		Year Ended
	30-Sep-11	30-Sep-10	30-Sep-11	30-Sep-10	31-Mar-11
Total Income					
Net Sales/Income from Operations	1,674	1,173	3,260	2,258	5,003
Other Income	34	13	57	26	58
	1,709	1,186	3,318	2,284	5,061
Expenses					
Cost of Sales	1,018	689	1,999	1,352	3,070
Other Expenses	306	236	573	427	900
	1,324	925	2,572	1,778	3,970
Profit Before Interest, Amortization, Depreciation & Tax	385	261	746	506	1,091
Product Development Expenses Written off	43	65	87	119	168
Depreciation	18	11	27	20	47
Profit before Interest & Tax	324	186	632	366	875
Interest	36	11	72	20	75
Profit before Tax	287	175	559	346	800
Tax	64	8	115	27	65
Profit before Minority interest	224	168	445	319	736
Minority interest	22	5	27	13	36
Net Profit	202	163	418	306	700
Basic Earnings Per Share (INR)	1.68	1.36	3.48	2.55	5.83
Diluted Earnings Per Share (INR)	1.68	1.36	3.48	2.55	5.83

GROWTH TRENDS



REVENUE ANALYSIS



Earnings Call Invite

The company will conduct a conference call for investors and analysts on **Friday, October 28, 2011 at 04:00 P.M. Indian Standard Time (IST)**, where the senior management will discuss the company's performance and answer questions from the participants.

The call will be hosted by Almondz Global Securities Limited.

The conference call details are as below:

Conference Access Numbers:

Primary number +91 22 4039 2326

Secondary number +91 22 3065 2473

Local Access number 6000 1221

Available in - Delhi, Bangalore, Chennai, Hyderabad, Kolkata

(Accessible from all major carriers except BSNL/MTNL)

3940 3977

Available in - Gurgaon (NCR), Bangalore, Kolkata, Cochin, Pune, Lucknow, Ahmedabad, Chandigarh

(Accessible from all carriers)

Participants are requested to dial-in 10 minutes in advance.

About TAKE Solutions

TAKE Solutions Ltd. [BSE: 532890 | NSE: TAKE] is a leading global business technology company with domain expertise in Life Sciences (LS) and Supply Chain Management (SCM). TAKE provides cost-effective and comprehensive solutions for enterprises across diverse sectors including pharmaceuticals, high technology, consumer packaged goods, oil/gas, and automotive. TAKE's SCM product suite includes distinct technology with embedded IP that spans enterprise mobility, trading partner collaboration, and material tracking. In the LS domain, TAKE offers IP-based software and extensive knowledge-based solutions to enable efficient clinical, regulatory, safety and commercialization processes.

TAKE has been recognized as a leader by IDC's MarketScape Worldwide Life Sciences R&D IT Outsourcing for 2011. TAKE's global headquarters is in Chennai, India; its U.S. headquarters is located in Princeton, New Jersey. TAKE has a proven track record as a trusted partner in delivering world-class solutions to more than 400 customers worldwide. For more information, please visit www.takesolutions.com.

Disclaimer:

Certain statements in this release concerning our future growth prospects are forward- looking statements, which involve a number of risks, and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding fluctuations in earnings, our ability to manage growth, intense competition in IT including factors which may affect our cost advantage, wage increases, our ability to attract and retain highly skilled professionals, client concentration, restrictions on immigration, our ability to manage our international operations, reduced demand for technology in SCM & Life Sciences, disruptions in telecommunication networks, our ability to successfully complete and integrate potential acquisitions, liability for damages on our contracts, withdrawal of governmental fiscal incentives, political instability, legal restrictions on raising capital or acquiring companies outside India, and unauthorized use of our intellectual property and general economic conditions affecting our industry. TAKE does not undertake to update any forward-looking statement that may be made from time to time by or on behalf of the company.

For more details, please contact:**Sachin Garg**

Assistant Vice President - Investor Relations
HP: +91- 99625 45467/ +65 - 929 79748
sachingarg@takesolutions.com

Dhiraj Rajpal / Mayank Vaswani

Citigate Dewe Rogerson
Tel: +91 – 22 – 6645 1241/30
dhiraj@cdr-india.com/mayank@cdr-india.com